Treatment for Dry Eye in Sjögren's Syndrome When Artificial Tears Have Not Worked
Patients with Sjögren's syndrome experience both dry eye and dry mouth as part of a systemic autoimmune process. When first-line lubricant therapy does not achieve adequate tear-film control, a more targeted treatment step is warranted.
Clinical Scenario
Sjögren's syndrome is a systemic autoimmune inflammatory disease that causes dry eye and dry mouth. The active inflammatory component means lubricant replacement alone often fails to restore a stable tear film in moderate-to-severe disease.
Why the Previous Treatment Was Insufficient
Initial management with artificial tear substitutes — lubricant solutions, gels, ointments, or a hydroxypropyl cellulose ocular insert — did not achieve stabilisation of the tear film, a prolonged tear break-up time, or a decrease in tear osmolarity. Failure to reach these targets signals that lubrication alone cannot address the underlying inflammatory drive and escalation is required.
Next-Step Approach
The next step adds an anti-inflammatory agent directed at the ocular surface. The specific agent and its intended duration of use depend on disease severity and whether short-term relief or long-term chronic management is the goal. An oral agent that addresses systemic secretory dysfunction may also be incorporated alongside the ophthalmic component. Full agent selection, sequencing, and monitoring details are in the structured protocol.
Clinical goals include significant improvement in dry eye symptoms — notably reduced itching and clearer vision — with full benefit typically emerging over four to eight weeks.
- Sjogren's syndrome is a systemic autoimmune inflammatory disease that causes dry eye and dry mouth.
- Ophthalmic corticosteroids decrease symptoms and signs of dry eye by decreasing inflammation and may be used on a short-term basis, normally several weeks, for moderate-to-severe dry eye.
- Cyclosporine ophthalmic emulsion 0.05% (Restasis) is the anti-inflammatory agent prescribed for long-term use in patients with chronic moderate-to-severe DED.
- There is evidence that either of these cholinergic agonists may also slightly improve dry eye symptoms in Sjogren's syndrome patients.
- This medication is quite effective in decreasing dry eye signs and symptoms in many patients, with full effect seen after four to eight weeks.